Next-generation veterinary vaccine economics — mRNA platform ROI, speed-to-market value, variant coverage economics, and novel antigen development cost-benefit. The financial framework for the future of animal vaccination.
Directly compare mRNA platform vaccines against conventional (killed, MLV, subunit) vaccines across efficacy, duration, production speed, cold chain requirements, and total cost of ownership. The decision framework for next-gen adoption.
Calculate the economic value of mRNA's rapid response capability — the ability to design and deploy a new vaccine in weeks rather than years. Quantifies the disease-days-prevented advantage of fast response during emerging disease events.
Calculate the economic value of broader variant coverage from mRNA and next-gen vaccines. Rapidly mutating pathogens (PRRS, AI, influenza) cause vaccine breaks when strains drift — quantify the cost of strain mismatch and the value of broader coverage.
Calculate the ROI of investing in novel antigen or platform development for a currently unvaccinated disease. For industry groups, integrators, or large operations with sufficient scale to justify custom vaccine development.
VS8 is the first dedicated economic calculator suite for next-generation veterinary vaccines. These models quantify the mRNA platform advantage — speed, breadth, adaptability — in financial terms that producers, integrators, and industry groups can use to make adoption and investment decisions. The future of animal vaccination has a compelling economic case. VS8 makes it visible.
For herd immunity modeling: VS7 Herd Immunity → · For epidemiology: VS5 Epidemiology → · ← VacStak Home
Research sources: Geall et al. mRNA veterinary vaccine economics; USDA-APHIS conditional license program; Moderna/BioNTech animal health mRNA pipeline; IDEXX Merck mRNA PRRS data. VacStak — vacstak.com · Patent Pending · US App 63/970,943.